

Fecha del CVA

16/07/2025

Parte A. DATOS PERSONALES

Nombre *	Rubén		
Apellidos *	Queiro Silva		
Sexo *	No Contesta	Fecha de Nacimiento *	
DNI/NIE/Pasaporte *		Teléfono *	
URL Web			
Dirección Email			
Identificador científico	Open Researcher and Contributor ID (ORCID) *	0000-0002-8418-7145	
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto	Facultativo especialista de área		
Fecha inicio	2005		
Organismo / Institución	Hospital Universitario Central de Asturias		
Departamento / Centro			
País		Teléfono	
Palabras clave			

A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Licenciado en Medicina y Cirugía	Universidad de Santiago de Compostela	1990

A.4. Indicadores generales de calidad de la producción científica

<https://orcid.org/0000-0002-8418-7145>

Scopus Author ID: 6603878341; Loop profile: 1247392; WOS Researcher ID: D-5358-2016; SciProfiles: 913083

40 artículos indexados en período 2023-24 (72.5% Q1, 57.% primer autor/correspondencia)

Web of Science Researcher Profile Summary

Metrics

Publications in Web of Science: 343

Total Times Cited: 4467

H-index: 35

Verified Reviews: 165

Verified Editors: 28

Trabajos más relevantes período 2023-24 (revistas Q1)

Patients With Psoriatic Arthritis-Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions.

Autor de correspondencia. J Rheumatol. 2024 Jul 1;51(7):682-686. doi: 10.3899/jrheum.2024-0016.

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.

Coautor (publicación grupo de trabajo EULAR). Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531.

Influence of the HLA-Cw6 Allele and IFIH1/MDA5 Gene Variants on the Cardiometabolic Risk Profile of Patients with Psoriatic Disease.

Primer autor. J Clin Med. 2024 Feb 1;13(3):845. doi: 10.3390/jcm13030845.

How do patient reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.

Coautor (grupo de trabajo internacional. IP para España). Rheumatology (Oxford). 2024 Jan 8;kead679. doi: 10.1093/rheumatology/kead679.

An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis.

Coautor (grupo de trabajo internacional. IP para España). Rheumatology (Oxford). 2023 Nov 27;kead621. doi: 10.1093/rheumatology/kead621.

The IFIH1/MDA5 rs1990760 Gene Variant (946Thr) Differentiates Early- vs. Late-Onset Skin Disease and Increases the Risk of Arthritis in a Spanish Cohort of Psoriasis.

Autor de correspondencia. Int J Mol Sci. 2023 Sep 30;24(19):14803. doi: 10.3390/ijms241914803.

EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis.

Coautor (grupo de trabajo EULAR. IP para España). Ann Rheum Dis. 2023 Sep;82(9):1162-1170. doi: 10.1136/ard-2023-224148.

The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.

Autor de correspondencia. Front Immunol. 2023 Aug 4;14:1191782. doi: 10.3389/fimmu.2023.1191782.

Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.

Primer autor. Front Immunol. 2023 Jul 18;14:1203372. doi: 10.3389/fimmu.2023.1203372.

Bimekizumab in psoriatic arthritis: a great leap forward?

Primer autor (revista de muy alto impacto). Lancet. 2023 Jan 7;401(10370):2-3. doi: 10.1016/S0140-6736(22)02423-0.

Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis.

Primer autor (trabajo con perspectiva de género). Clin Exp Rheumatol (Q2). 2023 Jan;41(1):137-144. doi: 10.55563/clinexprheumatol/077ul6.

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Licenciado en Medicina y Cirugía por la Universidad de Santiago de Compostela 1984-90.

Especialista en Reumatología MIR 1990-94

Doctor por la Universidad de Oviedo 2005. Sobresaliente Cum Laude. Premio extraordinario de tesis doctoral.

1995

MEDICO ADJUNTO DE URGENCIAS

HOSPITAL DA COSTA. BURELA. LUGO

1997-2001

MEDICO ADJUNTO DE REUMATOLOGIA

HOSPITAL ARANZAZU. SAN SEBASTIAN. GUIPUZCOA

2001-2005

MEDICO ADJUNTO DE REUMATOLOGIA

HOSPITAL SAN AGUSTIN. AVILES. ASTURIAS

2005-

MEDICO ADJUNTO DE REUMATOLOGIA

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

MIEMBRO DE LA SOCIEDAD ESPAÑOLA DE REUMATOLOGIA

SECRETARIO DEL GRUPO ESPAÑOL DE TRABAJO EN ARTRITIS PSORIASICA (GEAPSO-SER)

MIEMBRO DEL GRUPO DE TRABAJO INTERNACIONAL EN PSORIASIS Y ARTRITIS PSORIASICA (GRAPPA) ASESOR CIENTIFICO DE LAS ASOCIACIONES DE PACIENTES EUROPEOS CON PSORIASIS Y ARTRITIS PSORIASICA (EUROPSO)

PREMIO A LA EXCELENCIA EN INVESTIGACION DE LA FUNDACION ESPAÑOLA DE REUMATOLOGIA (2008)

Profesor Asociado del Dpto de Medicina de la universidad de Oviedo desde el curso 2019-actualidad.

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citas

- 1 **Artículo científico.** 2024. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. <https://doi.org/10.1136/ard-2024-225531>
- 2 **Artículo científico.** 2024. Influence of the HLA-Cw6 Allele and IFIH1/MDA5 Gene Variants on the Cardiometabolic Risk Profile of Patients with Psoriatic Disease. <https://doi.org/10.3390/jcm13030845>
- 3 **Artículo científico.** 2023. Bimekizumab in psoriatic arthritis: a great leap forward?. [https://doi.org/10.1016/S0140-6736\(22\)02423-0](https://doi.org/10.1016/S0140-6736(22)02423-0)
- 4 **Artículo científico.** 2023. Characteristics associated with the perception of high-impact disease (PsAID ≥ 4) in patients with recent-onset psoriatic arthritis. Machine learning-based model. <https://doi.org/10.1016/j.semarthrit.2022.152097>
- 5 **Artículo científico.** 2023. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. <https://doi.org/10.1136/ard-2023-224148>

- 6 **Artículo científico.** 2023. The IFIH1/MDA5 rs1990760 Gene Variant (946Thr) Differentiates Early- vs. Late-Onset Skin Disease and Increases the Risk of Arthritis in a Spanish Cohort of Psoriasis. <https://doi.org/10.3390/ijms241914803>
- 7 **Artículo científico.** 2023. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases (vol 14, 1191782, 2023). <https://doi.org/10.3389/fimmu.2023.1191782>
- 8 **Artículo científico.** 2023. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. <https://doi.org/10.3389/fimmu.2023.1191782>
- 9 **Artículo científico.** 2022. Confounders contributing to explain the association between sex and disease impact in patients with recent-onset psoriatic arthritis. <https://doi.org/10.55563/clinexprheumatol/077ul6>
- 10 **Artículo científico.** 2022. Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. <https://doi.org/10.1186/s13075-022-02838-2>
- 11 **Artículo científico.** 2021. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. <https://doi.org/10.3389/fmed.2021.679009>
- 12 **Artículo científico.** 2021. The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <https://doi.org/10.1002/acr.24174>
- 13 **Artículo científico.** 2019. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <https://doi.org/10.1136/annrheumdis-2018-214158>
- 14 **Artículo científico.** 2024. Are patients with Inflammatory Bowel Disease and two or more associated Immune-Mediated Inflammatory Diseases different from those with no or one associated disease?.
- 15 **Artículo científico.** 2024. Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion.
- 16 **Artículo científico.** 2024. Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients?.
- 17 **Artículo científico.** 2024. HLA-C*06–defined endotype in psoriatic disease: an ever-widening landscape.
- 18 **Artículo científico.** 2024. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
- 19 **Artículo científico.** 2024. In the search for an accurate and early diagnosis of psoriatic arthritis: is the key in ultrasound?.
- 20 **Artículo científico.** 2024. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: relationship with clinical parameters.
- 21 **Artículo científico.** 2024. Managing psoriatic arthritis in different clinical scenarios.
- 22 **Artículo científico.** 2024. Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions.
- 23 **Artículo científico.** 2024. Psoriatic nail complex: thick as thieves.
- 24 **Artículo científico.** 2024. The nail in psoriatic arthritis: new insights into prognosis and treatment.
- 25 **Artículo científico.** 2024. Ultrasound in Psoriatic Arthritis: Still Many Pending Issues.
- 26 **Artículo científico.** 2023. Accuracy of self-reporting of immune-mediated inflammatory diseases by patients with inflammatory bowel disease. Results from a hospital-based cohort.
- 27 **Artículo científico.** 2023. Acroosteolysis and facial dysmorphism: a new case of Hajdu-Cheney syndrome.
- 28 **Artículo científico.** 2023. Altered sleep in axial spondyloarthritis and psoriatic arthritis: Post hoc comparative study based on a sleep-specific question from the ASAS health index.
- 29 **Artículo científico.** 2023. An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain (Aug, 10.1007/s40122-022-00419-4, 2022).
- 30 **Artículo científico.** 2023. An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis.

- 31 **Artículo científico**. 2023. Are Patients with Axial Spondyloarthritis Who Were Breastfed Protected against the Development of Severe Disease?.
- 32 **Artículo científico**. 2023. Comment on: Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen.
- 33 **Artículo científico**. 2023. Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes.
- 34 **Artículo científico**. 2023. Disease impact in axial spondyloarthritis: Divergent roles between family history of disease and HLA-B27?.
- 35 **Artículo científico**. 2023. Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.
- 36 **Artículo científico**. 2023. Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations.
- 37 **Artículo científico**. 2023. Moderate-High Disease Activity in Patients with Recent-Onset Psoriatic Arthritis—Multivariable Prediction Model Based on Machine Learning.
- 38 **Artículo científico**. 2023. Osteomalacia in Adults: A Practical Insight for Clinicians.
- 39 **Artículo científico**. 2023. PsABIOnD Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis.
- 40 **Artículo científico**. 2023. Psoriatic Arthritis Impact of Disease (PsAID) questionnaire: closer to the all-in-one tool?.
- 41 **Artículo científico**. 2023. Reply to: The association between sex and disease impact cannot be confounded by clinical risk factors.
- 42 **Artículo científico**. 2023. Resources and Strategies for the Optimal Care of Patients With Axial Spondyloarthritis: The CREA Project.
- 43 **Artículo científico**. 2023. Strategies and resources to optimise the management of Psoriatic Arthritis patients: the CREA Project.
- 44 **Artículo científico**. 2023. Treatment Retention and Safety of Ixekizumab in Psoriatic Arthritis: A Real Life Single-Center Experience.
- 45 **Artículo científico**. 2022. Active Disease in Psoriatic Arthritis: An Assessment of Spondyloarthritis International Society Health Index (ASAS-HI)—based Analysis.
- 46 **Artículo científico**. 2022. An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain.
- 47 **Artículo científico**. 2022. Commentary: Sex-based medicine in psoriatic arthritis: Lessons learned from machine learning-based prediction models.
- 48 **Artículo científico**. 2022. Differentiating facets of quality of life between spondyloarthritis phenotypes: added value of the ASAS health index.
- 49 **Artículo científico**. 2022. Do NSAIDs Take Us Away From Treatment Goals in Axial Spondyloarthritis: A Story About Dysbiosis or Just a Matter of Bias?.
- 50 **Artículo científico**. 2022. Non-Physical Disease Facets in Spondyloarthritis: An ASAS Health Index-Based Analysis between Psoriatic Arthritis and Axial Spondyloarthritis.
- 51 **Artículo científico**. 2022. Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey.
- 52 **Artículo científico**. 2022. Potential Differences in the Cardiometabolic Risk Profile of Patients with Psoriatic Disease according to Their HLA-C * 06 Status.
- 53 **Artículo científico**. 2022. PsAID High-impact Disease in Psoriatic Arthritis: A Component Weighting Analysis of the Assessment of SpondyloArthritis international Society Health Index.
- 54 **Artículo científico**. 2022. Resources and strategies for the optimal care of patients with axial spondyloarthritis: The CREA project.
- 55 **Artículo científico**. 2022. Severe Disease in Patients With Recent-Onset Psoriatic Arthritis. Prediction Model Based on Machine Learning.
- 56 **Artículo científico**. 2022. Strategies and resources to optimise the management of Psoriatic Arthritis patients: The CREA Project.
- 57 **Artículo científico**. 2021. A comparison of disease impact according to the cardiometabolic risk profile in psoriatic arthritis.
- 58 **Artículo científico**. 2021. ASAS Health Index as an Addition to Routine Clinical Practice.

- 59 **Artículo científico**. 2021. Artritis psoriásica: interacción entre enfermedades cardiometabólicas y la actividad inflamatoria de la enfermedad.
- 60 **Artículo científico**. 2021. Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine?.
- 61 **Artículo científico**. 2021. Construct validity of The Routine Assessment of Patient Index Data 3 (RAPID3) in the evaluation of axial spondyloarthritis.
- 62 **Artículo científico**. 2021. Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis.
- 63 **Artículo científico**. 2021. Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study.
- 64 **Artículo científico**. 2021. Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey.
- 65 **Artículo científico**. 2021. Female psoriatic arthritis: not just a matter of greater disease activity but of greater routine life impact.
- 66 **Artículo científico**. 2021. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study.
- 67 **Artículo científico**. 2021. Genetic Variants of the NF-κB Pathway: Unraveling the Genetic Architecture of Psoriatic Disease.
- 68 **Artículo científico**. 2021. Hyperlipidaemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy.
- 69 **Artículo científico**. 2021. Inflammation-fatigue in spondyloarthritis: a clear link in axial spondyloarthritis but less so in psoriatic arthritis.
- 70 **Artículo científico**. 2021. Management of particular clinical situations in psoriatic arthritis: an expert's recommendation document based on systematic literature review and extended Delphi process.
- 71 **Artículo científico**. 2021. Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey.
- 72 **Artículo científico**. 2021. Quality Certification Standard Proposal "SpACE" for Axial Spondyloarthritis Treatment Units.
- 73 **Artículo científico**. 2021. Quality certification standard proposal "SpACE" for axial spondyloarthritis treatment units.
- 74 **Artículo científico**. 2021. Sexual disinterest among spondyloarthritis patients. Comparison between psoriatic arthritis and axial spondyloarthritis using a sexuality-specific question from the ASAS Health Index.
- 75 **Artículo científico**. 2021. Sexual disinterest in spondyloarthritis patients. Comparison between psoriatic arthritis and axial spondyloarthritis using a sexuality-specific question from the ASAS Health Index.
- 76 **Artículo científico**. 2021. The ASAS health index: a new era for health impact assessment in spondyloarthritis.
- 77 **null**. 2021. Comparisons of Comorbidities in Patients with Ankylosing Spondylitis and Psoriatic Arthritis and their Influence on Psoriatic Arthritis Disease Activity: Results of a Multicentre Longitudinal Study.
- 78 **null**. 2021. Disease impact in axial spondyloarthritis: Divergent roles between family history of disease and HLA-B27?.

C.3. Proyectos y Contratos

- 1 **Proyecto**. Identificación de biomarcadores diagnósticos y pronósticos en la artritis psoriásica mediante la aplicación del riesgo poligénico". PI22/00804.. 2023-2025.
- 2 **Proyecto**. Registro español de artritis psoriásica de reciente inicio". REAPSER. 2023-2025.
- 3 **Proyecto**. Análisis integrado mediante tecnologías ómicas e inteligencia artificial para la identificación e implementación de herramientas de medicina personalizada en las espondiloartritis". PMP21/00119. 2022-2025.
- 4 **Proyecto**. Farmacogenética de los tratamientos biológicos en la Psoriasis/Artritis Psoriásica: análisis de las vías TNF/CARD14/NFKB/IL-17 mediante secuenciación masiva de genes candidatos. Desde 2013.
- 5 **Proyecto**. PROYECTO IMID-KIT PARA GENOTIPADO MASIVO EN ENFERMEDADES DE BASE INMUNE. Desde 2008.

C.6. Dirección de tesis doctorales y/o trabajos de fin de estudios

- 1** Frecuencia y factores asociados a la aterosclerosis subclínica en pacientes con artritis psoriásica bajo tratamiento sistémico. Universidad de Santiago de Compostela. 22/06/2020.
- 2** Estudio comparativo del perfil de los factores de riesgo cardiovascular clásicos entre pacientes con artritis psoriásica y pacientes con psoriasis. Universidad de Oviedo. 12/01/2017.